Tuberous Sclerosis Complex
Tuberous sclerosis complex (TSC), also known as Bourneville disease, is an inherited multisystem disorder belonging to the neurocutaneous syndromes (phakomatoses), affecting roughly 1 in 6,000 to 1 in 10,000 live births. It is characterized by benign growths called hamartomas, which can nonetheless compress and disrupt the structure and function of vital organs including the skin, brain, kidneys, heart, lungs and eyes.
Molecular basis:
- TSC is caused by a heterozygous loss-of-function mutation in one of two genes: TSC1 (on chromosome 9q34, encoding the protein hamartin) or TSC2 (on chromosome 16p13.3, encoding the protein tuberin).
- Normally, the hamartin–tuberin complex acts as a GTPase-activating protein that switches off Rheb, thereby suppressing mTORC1 (mammalian target of rapamycin complex 1) signaling – the pathway that regulates cell growth, division and protein synthesis.
- A mutation in TSC1 or TSC2 removes this brake entirely, leading to hyperactivation of mTORC1, uncontrolled cell proliferation and hamartomas throughout the body. About 30% of cases are inherited in an autosomal dominant pattern, while the remaining 70% arise from new (de novo) mutations.
Skin findings are the earliest clinical signs and occur in more than 90% of people with TSC. A dermatologist who recognizes them accurately can make the diagnosis early, allowing timely action to prevent serious neurological complications (epilepsy, intellectual disability) and kidney or lung failure.
Clinical Features and Skin Signs
The skin lesions of TSC appear at different ages, following a very characteristic sequence:
- Classic Skin Signs:
- Ash-leaf macules: Well-defined, grayish-white hypopigmented patches shaped like an ash leaf (or a teardrop). They are the earliest skin sign, present at birth or in infancy before age 1, usually on the trunk and limbs.
- Facial angiofibromas (formerly misnamed adenoma sebaceum): Appear between ages 2 and 5. These are shiny red, pink or skin-colored papules, 1–3 mm in size, spread symmetrically in a butterfly distribution over the nose, cheeks and chin, often with fine surface blood vessels.
- Shagreen patch: Develops in adolescence. A thickened, firm, slightly raised plaque, skin-colored or pale orange, with a bumpy texture like orange peel or leather, usually over the lower back.
- Ungual fibromas (Koenen tumors): Soft fibrous growths emerging from the nail folds of the fingers or toes or from beneath the nail plate, typically after puberty.
- Confetti macules: Numerous tiny 1–3 mm pale spots scattered over the shins and forearms.
- Involvement of Internal Organs:
- Central nervous system: Cortical tubers, subependymal nodules (SEN) and subependymal giant cell astrocytomas (SEGA), which can block the flow of cerebrospinal fluid and raise intracranial pressure. Clinically this shows up as seizures/epilepsy (notably West syndrome in infants) and autism or intellectual disability (TAND – TSC-associated neuropsychiatric disorders).
- Kidneys: Bilateral renal angiomyolipomas (AML), which carry a risk of sudden hemorrhage or chronic kidney failure.
- Heart: Benign cardiac rhabdomyomas, often detected on fetal or newborn ultrasound, which tend to regress as the child grows.
- Lungs: Lymphangioleiomyomatosis (LAM), seen especially in adult women with TSC, causing recurrent pneumothorax and respiratory failure.
TSC vs. Neurofibromatosis Type 1 (NF1)
| Feature | Tuberous Sclerosis Complex (TSC) | Neurofibromatosis Type 1 (NF1) |
|---|---|---|
| Gene | TSC1 or TSC2 mutation | NF1 gene mutation |
| Pigmentary lesions | Ash-leaf hypopigmented macules | Café-au-lait macules (CALMs ≥ 6) |
| Facial/skin tumors | Angiofibromas on the nose, cheeks and chin | Neurofibromas anywhere on the body |
| Nervous system | Cortical tubers, SEGA, seizures, autism | Optic pathway glioma, spinal tumors, mild learning difficulties |
| Internal organs | Renal angiomyolipoma (AML), pulmonary LAM, cardiac rhabdomyoma | Malignant peripheral nerve sheath tumor (MPNST), pheochromocytoma |
Diagnosis and Clinical Management at Haute-Derma
When we see a patient with long-standing pale patches since childhood or facial angiofibromas, Haute-Derma follows strict diagnostic criteria and a structured management pathway:
Updated TSC Diagnostic Criteria (International TSC Consensus Conference 2021)
A definite diagnosis of TSC requires 2 major criteria, OR 1 major criterion plus ≥ 2 minor criteria, OR genetic testing that identifies a pathogenic variant in TSC1 or TSC2.
- Major Criteria:
- ≥ 3 hypomelanotic macules (at least 5 mm across).
- ≥ 3 facial angiofibromas or a fibrous cephalic plaque.
- ≥ 2 ungual fibromas.
- Shagreen patch.
- Multiple retinal hamartomas.
- Cortical dysplasias / tubers.
- Subependymal nodules (SEN).
- Subependymal giant cell astrocytoma (SEGA).
- Cardiac rhabdomyoma.
- Lymphangioleiomyomatosis (LAM).
- ≥ 2 renal angiomyolipomas.
- Minor Criteria:
- Confetti skin lesions.
- ≥ 3 dental enamel pits.
- ≥ 2 intraoral fibromas.
- Retinal achromic patch.
- Multiple renal cysts.
- Non-renal hamartomas.
Topical Treatment and Cosmetic Contraindications
- Topical mTOR Inhibitors for Facial Angiofibromas (Topical Sirolimus / Rapamycin): Daily sirolimus 0.1%–0.2% cream or gel is the standard first-line treatment. It shrinks angiofibromas and reduces redness and visible vessels without any invasive procedure.
- Laser Treatment (When Needed): Pulsed dye laser (PDL, 595 nm) for redness and dilated vessels, combined with ultrapulse CO2 laser to ablate large, overgrown angiofibromas.
- Avoid Scrubbing, Strong Chemical Peels and Microneedling: Microneedling, needle rollers and chemical peels should not be used on angiofibromas or shagreen patches, as they can cause bleeding, secondary infection and irritation that makes the growths flare and thicken.
Prompt Multidisciplinary Screening
Because TSC can damage many organs, Haute-Derma coordinates referrals to specialist centers:
- Neurology: Brain MRI to screen for SEGA and cortical tubers; EEG to detect silent epileptic activity.
- Nephrology: Abdominal ultrasound or CT/MRI to measure renal angiomyolipomas (AML). For an AML larger than 3 cm that is growing, an oral systemic mTOR inhibitor (everolimus / sirolimus) is prescribed to shrink the tumor and reduce the risk of emergency hemorrhage.
- Pulmonology (women over 18): Chest HRCT to screen for LAM.
- Genetic counseling: TSC1/TSC2 gene testing for the patient and screening of family members.
